Merck KGaA (FRA:MRK) has been assigned a €115.00 ($136.90) target price by investment analysts at Kepler Capital Markets in a research report issued on Wednesday. The brokerage currently has a “buy” rating on the healthcare company’s stock. Kepler Capital Markets’ target price would indicate a potential upside of 28.26% from the stock’s previous close.

MRK has been the topic of a number of other research reports. Oddo Bhf set a €125.00 ($148.81) target price on shares of Merck KGaA and gave the company a “buy” rating in a research report on Friday, November 10th. JPMorgan Chase & Co. set a €100.00 ($119.05) target price on shares of Merck KGaA and gave the company a “neutral” rating in a research report on Friday, October 6th. Citigroup set a €123.00 ($146.43) target price on shares of Merck KGaA and gave the company a “buy” rating in a research report on Monday, September 25th. Goldman Sachs Group set a €105.00 ($125.00) target price on shares of Merck KGaA and gave the company a “neutral” rating in a research report on Tuesday, September 19th. Finally, UBS Group set a €120.00 ($142.86) target price on shares of Merck KGaA and gave the company a “buy” rating in a research report on Monday, January 8th. Twelve analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of €107.57 ($128.06).

Merck KGaA (MRK) traded down €0.46 ($0.55) during trading on Wednesday, hitting €89.66 ($106.74). 675,971 shares of the company were exchanged. Merck KGaA has a 52 week low of €87.33 ($103.96) and a 52 week high of €115.00 ($136.90). The firm has a market cap of $11,650.00 and a P/E ratio of 21.00.

ILLEGAL ACTIVITY NOTICE: “Merck KGaA (MRK) Given a €115.00 Price Target at Kepler Capital Markets” was originally posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this story on another website, it was illegally stolen and republished in violation of US and international copyright laws. The legal version of this story can be accessed at https://theolympiareport.com/2018/01/19/merck-kgaa-mrk-given-a-115-00-price-target-at-kepler-capital-markets.html.

About Merck KGaA

MERCK Kommanditgesellschaft auf Aktien provides products in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat colorectal cancer, head and neck tumors, multiple sclerosis, infertility, growth hormone disorders, cardiovascular disorders, diabetes, and thyroid disorders; diagnostics and prescription drugs for allergen immunotherapy; and biosimilars for oncology and inflammatory disorders.

Analyst Recommendations for Merck KGaA (FRA:MRK)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.